Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

917
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
917
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

980
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
980
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

741
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
741
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

287
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
287

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Periprocedural Factor Xa Inhibitor Interruption and Resumption for Patients With Atrial Fibrillation Undergoing Dental Procedures.

Korean circulation journal·2026
Same author

Combined Effect of Genetic Predisposition and Socioeconomic Deprivation on Atrial Fibrillation Risk.

European journal of preventive cardiology·2026
Same author

Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study.

European heart journal·2026
Same author

Increased Right Atrial FDG Uptake in Persistent Atrial Fibrillation: Insights Across Young vs. Old Age Groups.

Korean circulation journal·2026
Same author

Direct oral anticoagulants in very elderly and high-bleeding-risk patients with atrial fibrillation often excluded from oral anticoagulation therapy: a nationwide population-based cohort study.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2025
Same author

Atrial fibrillation burden and symptom, quality of life, and healthcare resource utilization after cryoballoon ablation in persistent atrial fibrillation.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2025

Related Experiment Video

Updated: Jun 28, 2025

Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.6K

Neuromodulation for Atrial Fibrillation Control.

Seil Oh1

  • 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. seil@snu.ac.kr.

Korean Circulation Journal
|April 24, 2024
PubMed
Summary

Neuromodulation offers options for managing atrial fibrillation (AF) by targeting the autonomic nervous system. Noninvasive vagus nerve stimulation presents a promising, potentially widely applicable approach for AF treatment.

Keywords:
Atrial fibrillationAutonomic nervesDenervationGanglionated plexusStimulation

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

3.2K

Related Experiment Videos

Last Updated: Jun 28, 2025

Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.6K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

3.2K

Area of Science:

  • Cardiovascular Research
  • Autonomic Neuroscience
  • Medical Device Innovation

Background:

  • The autonomic nervous system significantly influences atrial fibrillation (AF), particularly paroxysmal AF.
  • Neuromodulation strategies are being explored for AF management, targeting both efferent and afferent pathways.
  • Current neuromodulation techniques face challenges such as invasiveness, procedural completeness, and reinnervation.

Purpose of the Study:

  • To review neuromodulation strategies for managing atrial fibrillation (AF).
  • To evaluate the potential of efferent and afferent pathway modulation for AF treatment.
  • To highlight noninvasive afferent stimulation, specifically auditory vagus nerve stimulation, as a promising approach.

Main Methods:

  • Review of existing and investigational neuromodulation techniques for AF.
  • Analysis of efferent pathway modulation: permanent vs. temporary block (e.g., botulinum toxin), subthreshold stimulation.
  • Exploration of afferent pathway modulation: renal denervation, auditory vagus nerve stimulation.

Main Results:

  • Permanent efferent nerve block is challenging due to procedural limitations and reinnervation.
  • Temporary efferent block (e.g., botulinum toxin) is a potential option for post-cardiac surgery AF.
  • Noninvasive auditory vagus nerve stimulation is a low-level afferent stimulation method with potential for widespread use if efficacy is proven.

Conclusions:

  • Neuromodulation targeting the autonomic nervous system is a viable strategy for AF management.
  • Auditory vagus nerve stimulation offers a noninvasive, easily applicable method for AF treatment.
  • Further research is needed to confirm the efficacy of auditory vagus nerve stimulation for broad clinical adoption.